http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 27 Feb 2026 08:02:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31/26076019.html si-local-file:///var/storage/secattach/20260227/26076019.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31/26076019.html Fri, 27 Feb 2026 08:02:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31/26076019.html si-local-file:///var/storage/secattach/20260227/26076019.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31/26076019.html Fri, 27 Feb 2026 08:02:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++425++++++++VYNE+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+VYNE+Therapeutics+Inc./25923646.html si-local-file:///var/storage/secattach/20260130/25923646.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++VYNE+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+VYNE+Therapeutics+Inc./25923646.html Fri, 30 Jan 2026 16:12:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++425++++++++VYNE+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+VYNE+Therapeutics+Inc./25923646.html si-local-file:///var/storage/secattach/20260130/25923646.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++VYNE+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+VYNE+Therapeutics+Inc./25923646.html Fri, 30 Jan 2026 16:12:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VYNE+Therapeutics+Inc.++++For%3A+Jan+30/25923635.html si-local-file:///var/storage/secattach/20260130/25923635.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VYNE+Therapeutics+Inc.++++For%3A+Jan+30/25923635.html Fri, 30 Jan 2026 16:11:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VYNE+Therapeutics+Inc.++++For%3A+Jan+30/25923635.html si-local-file:///var/storage/secattach/20260130/25923635.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VYNE+Therapeutics+Inc.++++For%3A+Jan+30/25923635.html Fri, 30 Jan 2026 16:11:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Harsch+Mutya/25801873.html si-local-file:///var/storage/secattach/20260105/25801873.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Harsch+Mutya/25801873.html Mon, 05 Jan 2026 08:30:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Harsch+Mutya/25801873.html si-local-file:///var/storage/secattach/20260105/25801873.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Harsch+Mutya/25801873.html Mon, 05 Jan 2026 08:30:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Zeronda+Tyler/25801880.html si-local-file:///var/storage/secattach/20260105/25801880.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Zeronda+Tyler/25801880.html Mon, 05 Jan 2026 08:30:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Zeronda+Tyler/25801880.html si-local-file:///var/storage/secattach/20260105/25801880.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Zeronda+Tyler/25801880.html Mon, 05 Jan 2026 08:30:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Stuart+Iain/25801882.html si-local-file:///var/storage/secattach/20260105/25801882.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Stuart+Iain/25801882.html Mon, 05 Jan 2026 08:30:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Stuart+Iain/25801882.html si-local-file:///var/storage/secattach/20260105/25801882.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Stuart+Iain/25801882.html Mon, 05 Jan 2026 08:30:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Domzalski+David/25801893.html si-local-file:///var/storage/secattach/20260105/25801893.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Domzalski+David/25801893.html Mon, 05 Jan 2026 08:30:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Domzalski+David/25801893.html si-local-file:///var/storage/secattach/20260105/25801893.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+31++Filed+by%3A+Domzalski+David/25801893.html Mon, 05 Jan 2026 08:30:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++425++++++++VYNE+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+VYNE+Therapeutics+Inc./25750279.html si-local-file:///var/storage/secattach/20251217/25750279.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++VYNE+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+VYNE+Therapeutics+Inc./25750279.html Wed, 17 Dec 2025 08:17:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++425++++++++VYNE+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+VYNE+Therapeutics+Inc./25750279.html si-local-file:///var/storage/secattach/20251217/25750279.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++VYNE+Therapeutics+Inc.+++++++++++++++++Filed+by%3A+VYNE+Therapeutics+Inc./25750279.html Wed, 17 Dec 2025 08:17:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+17/25750273.html si-local-file:///var/storage/secattach/20251217/25750273.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+17/25750273.html Wed, 17 Dec 2025 08:16:00 -0500 O.37307441 VYNE http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+17/25750273.html si-local-file:///var/storage/secattach/20251217/25750273.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VYNE+Therapeutics+Inc.++++For%3A+Dec+17/25750273.html Wed, 17 Dec 2025 08:16:00 -0500 O.37307441 VYNE http://www.streetinsider.com/Corporate+News/VYNE+Therapeutics+and+Yarrow+Bioscience+announce+merger+agreement/25750190.html <p>VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. announced they have entered into a definitive merger agreement for an all-stock transaction. Upon completion, the combined company will operate as Yarrow Bioscience, Inc. and trade on NASDAQ under the ticker symbol "YARW".</p><p>The merger includes pre-closing private financings totaling approximately $200 million led by RTW Investments, with participation from OrbiMed, Janus Henderson Investors, venBio Partners, Logos Capital, LifeSci Venture Partners and Perceptive Advisors. The combined company's cash balance at closing is expected to fund operations into 2028.</p><p>Under the merger terms, pre-merger VYNE stockholders will own approximately 3% of the combined company, http://www.streetinsider.com/Corporate+News/VYNE+Therapeutics+and+Yarrow+Bioscience+announce+merger+agreement/25750190.html Wed, 17 Dec 2025 08:01:41 -0500 VYNE http://www.streetinsider.com/Mergers+and+Acquisitions/VYNE+Therapeutics+and+Yarrow+Bioscience+announce+merger+agreement/25750190.html <p>VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. announced they have entered into a definitive merger agreement for an all-stock transaction. Upon completion, the combined company will operate as Yarrow Bioscience, Inc. and trade on NASDAQ under the ticker symbol "YARW".</p><p>The merger includes pre-closing private financings totaling approximately $200 million led by RTW Investments, with participation from OrbiMed, Janus Henderson Investors, venBio Partners, Logos Capital, LifeSci Venture Partners and Perceptive Advisors. The combined company's cash balance at closing is expected to fund operations into 2028.</p><p>Under the merger terms, pre-merger VYNE stockholders will own approximately 3% of the combined company, http://www.streetinsider.com/Mergers+and+Acquisitions/VYNE+Therapeutics+and+Yarrow+Bioscience+announce+merger+agreement/25750190.html Wed, 17 Dec 2025 08:01:41 -0500 VYNE http://www.streetinsider.com/Hot+Corp.+News/VYNE+Therapeutics+and+Yarrow+Bioscience+announce+merger+agreement/25750190.html <p>VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. announced they have entered into a definitive merger agreement for an all-stock transaction. Upon completion, the combined company will operate as Yarrow Bioscience, Inc. and trade on NASDAQ under the ticker symbol "YARW".</p><p>The merger includes pre-closing private financings totaling approximately $200 million led by RTW Investments, with participation from OrbiMed, Janus Henderson Investors, venBio Partners, Logos Capital, LifeSci Venture Partners and Perceptive Advisors. The combined company's cash balance at closing is expected to fund operations into 2028.</p><p>Under the merger terms, pre-merger VYNE stockholders will own approximately 3% of the combined company, http://www.streetinsider.com/Hot+Corp.+News/VYNE+Therapeutics+and+Yarrow+Bioscience+announce+merger+agreement/25750190.html Wed, 17 Dec 2025 08:01:41 -0500 VYNE http://www.streetinsider.com/Hot+M+and+A/VYNE+Therapeutics+and+Yarrow+Bioscience+announce+merger+agreement/25750190.html <p>VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. announced they have entered into a definitive merger agreement for an all-stock transaction. Upon completion, the combined company will operate as Yarrow Bioscience, Inc. and trade on NASDAQ under the ticker symbol "YARW".</p><p>The merger includes pre-closing private financings totaling approximately $200 million led by RTW Investments, with participation from OrbiMed, Janus Henderson Investors, venBio Partners, Logos Capital, LifeSci Venture Partners and Perceptive Advisors. The combined company's cash balance at closing is expected to fund operations into 2028.</p><p>Under the merger terms, pre-merger VYNE stockholders will own approximately 3% of the combined company, http://www.streetinsider.com/Hot+M+and+A/VYNE+Therapeutics+and+Yarrow+Bioscience+announce+merger+agreement/25750190.html Wed, 17 Dec 2025 08:01:41 -0500 VYNE http://www.streetinsider.com/Press+Releases/VYNE+Therapeutics+and+Yarrow+Bioscience+Announce+Merger+Agreement%C2%A0/25750085.html <ul type="disc"><li style="margin-bottom:8pt;"><em>Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) and thyroid eye disease (“TED”)</em></li><li style="margin-bottom:8pt;"><em>Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd (“GenSci”)</em></li><li style="margin-bottom:8pt;"><em>Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028</em></li><li http://www.streetinsider.com/Press+Releases/VYNE+Therapeutics+and+Yarrow+Bioscience+Announce+Merger+Agreement%C2%A0/25750085.html Wed, 17 Dec 2025 08:00:00 -0500 A.07414818 A.12939998 A.27120359 A.50200171 A.50213959 A.50216428 O.00478238 O.00637159 O.02836754 O.03227691 O.20113046 O.37307441 O.55864350 VYNE http://www.streetinsider.com/Press+Releases/VYNE+Therapeutics+and+Yarrow+Bioscience+Announce+Merger+Agreement%C2%A0/25750085.html <ul type="disc"><li style="margin-bottom:8pt;"><em>Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) and thyroid eye disease (“TED”)</em></li><li style="margin-bottom:8pt;"><em>Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd (“GenSci”)</em></li><li style="margin-bottom:8pt;"><em>Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028</em></li><li http://www.streetinsider.com/Press+Releases/VYNE+Therapeutics+and+Yarrow+Bioscience+Announce+Merger+Agreement%C2%A0/25750085.html Wed, 17 Dec 2025 08:00:00 -0500 A.07414818 A.12939998 A.27120359 A.50200171 A.50213959 A.50216428 O.00478238 O.00637159 O.02836754 O.03227691 O.20113046 O.37307441 O.55864350 VYNE http://www.streetinsider.com/Press+Releases/VYNE+Therapeutics+and+Yarrow+Bioscience+Announce+Merger+Agreement%C2%A0/25750085.html <ul type="disc"><li style="margin-bottom:8pt;"><em>Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) and thyroid eye disease (“TED”)</em></li><li style="margin-bottom:8pt;"><em>Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd (“GenSci”)</em></li><li style="margin-bottom:8pt;"><em>Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028</em></li><li http://www.streetinsider.com/Press+Releases/VYNE+Therapeutics+and+Yarrow+Bioscience+Announce+Merger+Agreement%C2%A0/25750085.html Wed, 17 Dec 2025 08:00:00 -0500 A.07414818 A.12939998 A.27120359 A.50200171 A.50213959 A.50216428 O.00478238 O.00637159 O.02836754 O.03227691 O.20113046 O.37307441 O.55864350 VYNE